全文获取类型
收费全文 | 375718篇 |
免费 | 43914篇 |
国内免费 | 3212篇 |
专业分类
耳鼻咽喉 | 7248篇 |
儿科学 | 11190篇 |
妇产科学 | 6717篇 |
基础医学 | 32065篇 |
口腔科学 | 5711篇 |
临床医学 | 49049篇 |
内科学 | 93397篇 |
皮肤病学 | 10481篇 |
神经病学 | 37330篇 |
特种医学 | 15946篇 |
外国民族医学 | 13篇 |
外科学 | 75367篇 |
综合类 | 2755篇 |
现状与发展 | 73篇 |
一般理论 | 177篇 |
预防医学 | 23145篇 |
眼科学 | 8666篇 |
药学 | 16277篇 |
1篇 | |
中国医学 | 326篇 |
肿瘤学 | 26910篇 |
出版年
2024年 | 785篇 |
2023年 | 5806篇 |
2022年 | 3279篇 |
2021年 | 8145篇 |
2020年 | 8644篇 |
2019年 | 7002篇 |
2018年 | 12934篇 |
2017年 | 11269篇 |
2016年 | 12659篇 |
2015年 | 13526篇 |
2014年 | 22835篇 |
2013年 | 25828篇 |
2012年 | 22248篇 |
2011年 | 23020篇 |
2010年 | 19722篇 |
2009年 | 22592篇 |
2008年 | 21198篇 |
2007年 | 20313篇 |
2006年 | 22197篇 |
2005年 | 19487篇 |
2004年 | 17815篇 |
2003年 | 15585篇 |
2002年 | 15078篇 |
2001年 | 5509篇 |
2000年 | 4263篇 |
1999年 | 5040篇 |
1998年 | 6206篇 |
1997年 | 5484篇 |
1996年 | 5081篇 |
1995年 | 4791篇 |
1994年 | 3349篇 |
1993年 | 2964篇 |
1992年 | 2285篇 |
1991年 | 2268篇 |
1990年 | 1802篇 |
1989年 | 1872篇 |
1988年 | 1667篇 |
1987年 | 1441篇 |
1986年 | 1493篇 |
1985年 | 1360篇 |
1984年 | 1433篇 |
1983年 | 1282篇 |
1982年 | 1523篇 |
1981年 | 1348篇 |
1980年 | 1179篇 |
1979年 | 756篇 |
1978年 | 833篇 |
1977年 | 826篇 |
1976年 | 638篇 |
1975年 | 583篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
131.
Ravinder K. Mittal MD Barry N. Siskind MD Michio Hongo MD M. Wayne Flye MD Richard W. McCallum MD 《Digestive diseases and sciences》1986,31(4):379-384
Three patients with dysphagia caused by compression of the distal esophagus by a tortuous nonaneurysmal atherosclerotic aorta are described. All three patients were elderly women; systemic hypertension and cardiomegaly were present in two patients. Barium studies of the esophagus showed displacement and compression of the distal esophagus by the thoracic aorta. Debilitating dysphagia was treated surgically in one patient. The other two patients had milder symptoms and were managed conservatively. Esophageal manometry in these three patients showed superimposed pulsations and elevated intraluminal pressure just proximal to the lower esophageal sphincter. To evaluate the significance of these manometric findings and their correlation with clinical symptoms, we reviewed manometric tracings in 47 normal subjects. Ten of these subjects had an elevation of baseline intraluminal esophageal pressure as a result of superimposed vascular pulsations. We conclude that (1) compression of the distal esophagus by a tortuous atherosclerotic aorta in the appropriate setting can lead to clinically significant dysphagia and (2) a manometric finding of vascular compression of the esophagus does not necessarily correlate symptomatic dysphagia. 相似文献
132.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
133.
134.
Improvement in the Appearance of Wrinkles with Topical Transforming Growth Factor β1 and l-Ascorbic Acid 总被引:1,自引:0,他引:1
MICHELLE EHRLICH MD JAGGI RAO MD ANJU PABBY MD MITCHEL P. GOLDMAN MD 《Dermatologic surgery》2006,32(5):618-625
BACKGROUND AND OBJECTIVE: Facial rhytides are a common cosmetic concern. Surgical treatment effects dramatic improvement; however, the associated risk and cost may be prohibitive. Recent focus is on developing topical products containing biologically active ingredients for at-home therapy. Our study examines the effects of a topical cream containing transforming growth factor-beta(1) (TGF-beta(1)), l-ascorbic acid, and Cimicifuga racemosa extract (CRS) (Topix Pharmaceuticals, North Amityville, NY, USA). MATERIALS AND METHODS: In the first arm of the study, 12 subjects were randomized to apply CRS to the left or right side of their face and a cream containing l-ascorbic acid and C. racemosa in silicone base (vitamin C [Vit C]) to the contralateral side twice daily for 3 months. In the second arm of the study, 20 subjects were randomized to apply CRS to the left or right side of their face and Tissue Nutrient Solution Recovery Complex (TNS) (SkinMedica, Carlsbad, CA, USA), a product containing a variety of growth factors including VEGF, PDGF-A, G-CSF, HGF, IL-6, IL-8, and TGF-beta(1) (Nouricel-MD) without l-ascorbic acid, C. racemosa extract, or silicone base, to the contralateral side of their face twice daily for 3 months. Digital photographs were scored by study-blinded physicians, and self-assessments were completed by all subjects at baseline and at the conclusion of the protocol. RESULTS: CRS and TNS were well tolerated, and all subjects completed the 3-month protocol for the CRS versus Vit C arm of the study. Physicians rated success in facial wrinkling scores on the CRS-treated side of the face for 27 of 31 subjects. Responders showed, on average, 21.7% improvement in physician-rated wrinkle scores. The mean improvement in the group of 31 patients as a whole was 12%. Eighteen of 31 subjects reported a noticeable improvement on their CRS-treated side. Both CRS and TNS demonstrate significant success between baseline and 3-month scores, and both growth factor products are superior to Vit C. Patients preferred CRS over TNS. CONCLUSION: CRS is effective in minimizing the appearance of facial rhytides. The success of the CRS product is largely attributable to the incorporation of TGF-beta(1). 相似文献
135.
136.
137.
Simultaneous angiographic late stent thrombosis in two different coronary vessels after withdrawal of the combined anti-platelet therapy 总被引:2,自引:2,他引:0
138.
Michael R Horsman 《International journal of hyperthermia》2006,22(3):197-203
The most important physiological parameter influencing tissue response to heat is blood flow. At mild hyperthermia temperatures blood perfusion increases in many tumours and this effect is heating time-, temperature- and tumour-dependent. These flow increases can improve tumour oxygenation. When heating is terminated, perfusion and oxygenation commonly recover, although how quickly this occurs appears to be tumour-specific. While these effects are unlikely to have any anti-tumour activity they can be exploited to improve the combination of heat with other therapies. However, since similar physiological effects should occur in normal tissues, such combination therapies must be carefully applied. Heating tumours to higher temperatures typically causes a transient increase in perfusion during heating, followed by vascular collapse which if sufficient will increase tumour necrosis. The speed and degree of vascular collapse is dependent on heating time, temperature and tumour model used. Such vascular collapse generally occurs at temperatures that cause a substantial blood flow increase in certain normal tissues, thus preferential anti-tumour effects can be achieved. The tumour vascular supply can also be exploited to improve the response to heat. Decreasing blood flow, using transient physiological modifiers or longer acting vascular disrupting agents prior to the initiation of heating, can both increase the accumulation of physical heat in the tumour, as well as increase heat sensitivity by changing the tumour micro-environmental parameters, primarily an increase in tumour acidity. Such changes are generally not seen in normal tissues, thus resulting in a therapeutic benefit. 相似文献
139.
140.